February 13, 2025

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule. The results have been published in the journal “Circulation”.

Source: Heidelberg University Hospital

The “Molecular and Cellular Modeling” group led by Rebecca Wade was part of the project. The approach was to integrate experiments on heart muscle cells and animals and computational molecular modeling. “Our lab developed a customized computer-aided modeling pipeline for this project to model the molecular structure of the peptide and interactions with the predicted molecular effectors in the diseased heart cells”, Wade says. “The computational modeling guided the design of specific experiments to investigate the molecular mechanisms.”

The framework for the successful cooperation was provided by the Informatics for Life (I4L) Initiative, which was funded by the Klaus Tschira Foundation. The project received further financial support from the German Center for Cardiovascular Research with translational project funding from the Federal Ministry of Education and Research from the “Preclinical Confirmatory Studies” program.

For more information see the press release of the Heidelberg University Hospital:
https://www.klinikum.uni-heidelberg.de/newsroom/en/therapeutic-designer-peptide-to-combat-acute-heart-muscle-weakness/

Publication:

Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models. Circulation. Published online November 21, 2024. doi:10.1161/CIRCULATIONAHA.123.066961

Scientific Contact:

Prof. Dr. Patrick Most 
Division of Molecular and Translational Cardiology
Department of Internal Medicine III 
Heidelberg University Hospital
Heidelberg Medical Faculty of Heidelberg University
patrick.most@med.uni-heidelberg.de

Prof. Dr. Rebecca Wade
Group Leader `Molecular and Cellular Modeling´
Heidelberg Institute for Theoretical Studies (HITS)
Center of Molecular Biology of Heidelberg University (ZMBH)
Heidelberg Medical Faculty of Heidelberg University

Press Contact:
Dr. Stefanie Seltmann
Head of Communications
Heidelberg University Hospital (UKHD)
presse@med.uni-heidelberg.de

Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
comms@h-its.org

Our latest News

discover more
BioMed X and Servier Launch First XSeed Labs in Europe

BioMed X and Servier Launch First XSeed Labs in Europe

Heidelberg, Germany / Paris, France, July 9th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe […]

Investigating kinase activity in living cells

Investigating kinase activity in living cells

Scientists build molecular recording tool The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research in Heidelberg have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This […]

The evolution of cancer cells decoded

The evolution of cancer cells decoded

Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp